Skip to main content
¿Necesita servicios de traducción?
Comuníquese con nuestra mesa de ayuda 24/7/365 al 877-635-9545.

Monitoring the Growth of the Obesity Medication Pipeline

The increased awareness and discussion around more effective weight management medications has resulted in obesity medication pipeline growth. Research and development is focusing on new dosage forms, oral versus injectable, and combinations with glucagon-like peptide-1 receptor agonists.  Currently, Eli Lilly and Company (Lilly) and Novo Nordisk dominate the pipeline for weight management medications.

Monitoring the Growth of the Obesity Medication Pipeline hero image
Product Manufacturer Route Frequency Class Maximum Average Weight Loss (Timeframe) Expected Approval
tirzepatide Lilly SC Once weekly GLP-1 receptor agonist 13.4%
(72 weeks)
Late 2023 -
Early 2024
semaglutide Novo Nordisk Oral Once daily GLP-1 receptor agonist 15.1%
(68 weeks)

2024

CagriSema (cagrilintide/semaglutide) Novo Nordisk SC Once weekly Amylin analog/GLP-1 receptor agonist 15.6%
(32 weeks)
2025
danuglipron Pfizer Oral Twice daily GLP-1 receptor agonist -5.4kg
(12 weeks)
2025
retatrutide Lilly SC Once weekly GIP/GLP-1/Glucagon receptor agonist

17.5%
(24 weeks)

24.2%
(28 weeks)

2026+
orforglipron Lilly Oral Once daily GLP-1 receptor agonist 14.7%
(36 weeks)
2026+

 

Reference source: https://www.clinicaltrialsarena.com/features/obesity-trials-to-watch/

ProAct Logo ProAct Logo ProAct Logo
mobile image tablet image desktop image